Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10345184 | 0.85 | OPRL1 (0.56) | ALDH1A1SMN1; SMN2SIGMAR1 | |
| Bromide SCHEMBL10345274 | 0.84 | OPRL1 (0.55) | ALDH1A1SMN1; SMN2SIGMAR1 | |
| SCHEMBL10345227 | 0.83 | CCR3 (0.60) | FAAHACHEALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL2341863 | 0.82 | SSTR5 (0.60) | ALDH1A1SMN1; SMN2KDM4ECHRM2CHRM3 | |
| SCHEMBL2342807 | 0.80 | CYP3A4 (0.57) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2336799 | 0.78 | MEN1 (0.55) | FAAHALDH1A1LMNAMAPT | |
| SCHEMBL11154544 | 0.78 | SIGMAR1 (0.52) | FAAHACHEMGLLALDH1A1SMN1; SMN2 | |
| SCHEMBL10345158 | 0.77 | CYP3A4 (0.50) | ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL1682089 | 0.77 | ALDH1A1 (0.55) | MGLLALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL5060914 | 0.77 | ALDH1A1 (0.80) | FAAHACHEMGLLALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956046-B2 | 4-hydroxypiperidine derivatives having analgesic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1391452-A1 | 4-HYDROXPIPERIDINE DERIVATIVE WITH ANALGETIC ACTIVITY | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | HNMT, HDAC1, HDAC3 | FAAH 591/4885ACHE 575/4885MGLL 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.